{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:35:01Z","timestamp":1760315701232,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2020,12,15]]},"abstract":"<jats:p>Quality\u2010of\u2010life analyses such as this one for the Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) help to better define the relative impact of treatments beyond disease progression metrics, including socioeconomics. Although there are no head\u2010to\u2010head comparisons of the recent major clinical trials demonstrating efficacy in first\u2010line therapy for intermediate\u2010 or poor\u2010risk metastatic renal cell carcinoma, data from quality\u2010adjusted time without symptoms of disease or toxicity analyses can be used to also determine potential quality\u2010of\u2010life gains and toxicity.<\/jats:p>","DOI":"10.1002\/cncr.33168","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T17:12:46Z","timestamp":1602004366000},"page":"5210-5212","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Life under the CABOSUN: Cabozantinib improves quality\u2010adjusted survival in comparison with sunitinib"],"prefix":"10.1002","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-141X","authenticated-orcid":false,"given":"Jeanny B.","family":"Aragon\u2010Ching","sequence":"first","affiliation":[{"name":"Genitourinary Cancer Program Inova Schar Cancer Institute Fairfax Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute Bethesda Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1002\/cncr.33169","article-title":"Quality\u2010adjusted survival with first\u2010line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)","volume":"126","author":"Chen RC","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.5.553"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.09.002"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0197"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.012"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398"},{"key":"e_1_2_4_8_1","unstructured":"US Food and Drug Administration.FDA grants regular approval to Cabometyx for first\u2010line treatment of advanced renal cell carcinoma.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010regular\u2010approval\u2010cabometyx\u2010first\u2010line\u2010treatment\u2010advanced\u2010renal\u2010cell\u2010carcinoma. Accessed July 13 2020."},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780091106"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92112-7"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.15.1039"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-1579-7"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003712258"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29888"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"issue":"2","key":"e_1_2_4_18_1","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jval.2019.04.385","article-title":"Quality adjusted time without symptoms of disease progression or toxicity (Q\u2010TWiST) of nivolumab plus ipilimumab (Nivo + Ipi) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk [abstract PCN264]","volume":"22","author":"Shah R","year":"2019","journal-title":"Value Health"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.05.010"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535290-000000000-00000"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.149"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33168","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:30:51Z","timestamp":1760272251000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":20,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2020,12,15]]}},"alternative-id":["10.1002\/cncr.33168"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33168","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"2020-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}